Immunomodulatory effects of two HIV protease inhibitors, Saquinavir and Ritonavir, on lymphocytes from healthy seronegative individuals

Immunology Letters

Volumn 111, Issue 2, 2007, Pages 111-115

  Delmonte, Ottavia M ^a   Bertolotto, Gabriella ^a   Ricotti, Emanuela ^a   Tovo, Pier Angelo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antiretroviral therapy; Cellular factors cytokines; Immune reconstitution; Protease inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD3 ANTIBODY; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; PHYTOHEMAGGLUTININ; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

CELL PROLIFERATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV PROTEASE INHIBITORS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES; RITONAVIR; SAQUINAVIR; T-LYMPHOCYTES;

EID: 34547699293     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.06.003     Document Type: Article

References (29)

1. Perrin L., and Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 280 (1998) 1871-1873
2. Ledergerber B., Egger M., Opravil M., Telenti A., Hirschel B., Battegay M., et al. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 13 (1999) 863-868
3. Heagy W., Crumpacker C., Lopez P.A., and Finger R.W. Inhibition of immune function by antiviral drugs. J Clin Invest 87 (1991) 1916-1924
4. André P., Groettrup M., Klenerman P., de Giuli R., Booth Jr. B.L., Cerundolo V., et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 95 (1998) 13120-13124
5. Tovo P.A. Highly active antiretroviral therapy inhibits cytokine production in HIV uninfected subjects. AIDS 14 (2000) 743-744
6. Schmidtke G., Holzhutter H.G., Bogyo M., Kairies N., Groll M., de Giuli R., et al. How inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 10 (1999) 35734-35740
7. Pajonk F., Himmelsbach J., Riess K., Sommer A., and McBride W.H. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 62 (2002) 5230-5235
8. Piccinini M., Rinaudo M.T., Chiapello N., Ricotti E., Baldovino S., Monstert M., et al. The human 26S proteasome is a target of antiretroviral agents. AIDS 16 (2002) 693-700
9. Piccinini M., Rinaudo M.T., Anselmino A., Biccinnà B., Ramondetti C., Dematteis A., et al. .The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther 10 (2005) 215-223
10. Keil K., Frerichs V.A., Di Francesco R., and Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit 25 (2003) 340-346
11. Equils O., Shapiro A., Madak Z., Liu C., and Lu D. Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation. Antimicrob Agents Chemother 48 (2004) 3905-3911
12. Laurent N., de Bouard S., Guillamo J.S., Christov C., Zini R., Jouault H., et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3 (2004) 129-136
13. Gaedicke S., Firat-Geier E., Constantiniu O., Lucchiari-Hartz M., Freudenberg M., Galanos C., et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 62 (2002) 6901-6908
14. Rechsteiner M., Realini C., and Ustrell V. The proteasome activator 11S REG (PA28) and Class I antigen presentation. Biochem J 345 (2000) 1-15
15. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17 (1998) 7151-7160
16. Baeuerle P.A., and Baltimore D. NF-kB: ten years after. Cell 87 (1996) 13-20
17. Karin M., and Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18 (2000) 621-663
18. Resino S., Galan I., Perez A., Leou J.A., Seoane E., Gurbindo D., et al. HIV-infected children with moderate-severe immune suppression: changes in the immune system after HAART. Clin Exp Immunol 137 (2004) 570-577
19. Hardy G.A., Imami N., Sullivan A.K., Pires A., Burton C.T., Nelson M.R., et al. Reconstitution of CD4+ T cell resposes in HIV-1 infected individuals initiating HAART is associated with renewed interleukin-2 production and responsivness. Clin Exp Immunol 134 (2003) 98-106
20. Angel J.B., Kumar A., Parato K., Filion L.J., Diaz-Mitoma F., Daftarian P., et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 177 (1998) 898-904
21. Johansson C.C., Bryn T., Yndestad A., Eikenh G., Bjerkell V., Froland S.S., et al. Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under control of c-AMP. AIDS 18 (2004) 327-328
22. Andersson J., Fehniger T.E., Patterson B.K., Pottage J., Agnoli M., Jones P., et al. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 30 (1998) F123-F129
23. Sloand E.M., Kumar P.N., Kim S., Chaudhuri A., Weichold F.F., and Young N.S. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 94 (1999) 1021-1027
24. Sloand E.M., Maciejewski J., Kumar P., Kim S., Chaudhuri A., and Young N. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood 96 (2000) 2735-2739
25. Mayne M., Bratanich A.C., Chen P., Rana F., Nath A., and Power C. HIV-1 tat molecular diversity and induction of TNF-alpha: implications for HIV-induced neurological disease. Neuroimmunomodulation 5 (1998) 184-192
26. Nath A., Conant K., Chen P., Scott C., and Major E.O. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. J Biol Chem 274 (1999) 17098-17102
27. Fine S.M., Maggirwar S.B., Elliott P.R., Epstein L.G., Gelbard H.A., and Dewhurst S. Proteasome blockers inhibit TNF-α release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. J Neuroimmunol 95 (1999) 55-64
28. Sgadari C., Monini P., Barillari G., and Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 4 (2003) 537-547
29. Wolf T., Findhammer S., Nolte B., Helm E.B., and Brodt H.R. Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors. Eur J Med Res 8 (2003) 17-24